Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
Open accessAbstract
Drug therapy often fails to control hypertension. Azilsartan medoxomil (AZL-M) is a newly developed angiotensin II receptor blocker with high efficacy and good tolerability. This double-blind, controlled, randomised trial compared its antihypertensive efficacy and safety vs the angiotensin-converting enzyme inhibitor ramipril (RAM) in patients with clinic systolic blood pressure (SBP) 150-180 mm Hg. Patients were randomised (n=884) to 20 mg AZL-M or 2.5 mg RAM once daily for 2 weeks, then force-titrated to 40 or 80 mg AZL-M or 10 mg RAM for 22 weeks. The primary endpoint was change in trough, seated, clinic SBP. Mean patient age was 57±11 years, 52.4% were male, 99.5% were Caucasian. Mean baseline BP was 161.1±7.9/94.9±9.0 mm Hg. Clinic SBP decreased by 20.6±0.95 and 21.2±0.95 mm Hg with AZL-M 40 and 80 mg vs12.2±0.95 mm Hg with RAM (P<0.001 for both AZL-M doses). Adverse events leading to discontinuation were less frequent with AZL-M 40 and 80 mg (2.4% and 3.1%, respectively) than with RAM (4.8%). These data demonstrated that treatment of stage 1-2 hypertension with AZL-M was more effective than RAM and better tolerated.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
24-hour ABPM studies demonstrate that azilsartan medoximil provides on average an additional 4 to 8 mm Hg further SBP reduction over other ARBs (eg, valsartan and olmesartan) or the ACE inhibitor ramipril.
“Specifically, 24-hour ABPM studies demonstrate that azilsartan medoximil provides on average an additional 4 to 8 mm Hg further SBP reduction over other ARBs (eg, valsartan and olmesartan) or the ACE inhibitor ramipril.381–383”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [383]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · see citing works
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,818 · see citing works
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407 · see citing works
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · see citing works
(2004) · PsycEXTRA Dataset · doi:10.1037/e442802008-001 · Cited by 2,882 · see citing works
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775 · see citing works
World Health Organization, I. S. O. H. W. G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,654 · see citing works
Wolf-Maier, K. (2003) · JAMA · doi:10.1001/jama.289.18.2363 · Cited by 1,717 · see citing works
O'Brien, E., Asmar, R., Beilin, L., Imai, Y., Mallion, J.-M., Mancia, G., Mengden, T., Myers, M., Padfield, P., Palatini, P., et al. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00001 · Cited by 1,655 · see citing works
Mann, J. F. E., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J. M., Wang, X., Maggioni, A. P., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,581 · see citing works
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016 · see citing works
Mancia, G., Laurent, S., Agabiti‐Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cífková, R., Clement, D. L., Coca, A., Dominiczak, A. F., et al. (2009) · Blood Pressure · doi:10.3109/08037050903450468 · Cited by 893 · see citing works
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812 · see citing works
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
Klingbeil, A. U., Schneider, M. P., Martus, P., Messerli, F. H., & Schmieder, R. E. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00158-x · Cited by 760 · see citing works
Blood Pressure Lowering Treatment Trialists’ Collaboration (2008) · BMJ · doi:10.1136/bmj.39548.738368.be · Cited by 739 · see citing works
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · see citing works
Mancia, G., Zanchetti, A., Agebiti-Rosei, E., Benemio, G., De Cesaris, R., Fogari, R., Pessino, A., Porcellati, C., Salvetti, A., & Trimarco, B. (1997) · Circulation · doi:10.1161/01.cir.95.6.1464 · Cited by 596 · see citing works
Mathew, J., Sleight, P., Lonn, E., Johnstone, D. E., Pogue, J., Yi, Q., Bosch, J., Sussex, B. A., Probstfield, J. L., & Yusuf, S. (2001) · Circulation · doi:10.1161/hc3901.096700 · Cited by 555 · see citing works
Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
Blood Pressure Lowering Treatment Trialists' Collaboration (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280bad9b4 · Cited by 411 · see citing works
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00035 · Cited by 392 · see citing works
Guidelines for the management of arterial hypertension
van de Borne, P. (2014) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · doi:10.2143/ac.69.1.3011345 · Cited by 348 · see citing works
White, W. B., Weber, M. A., Sica, D., Bakris, G. L., Perez, A., Cao, C., & Kupfer, S. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.163402 · Cited by 216 · see citing works
Self-citationOjima, M., Igata, H., Tanaka, M., Sakamoto, H., Kuroita, T., Kohara, Y., Kubo, K., Fuse, H., Imura, Y., Kusumoto, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176636 · Cited by 151 · see citing works
Bakris, G. L., Sica, D., Weber, M., White, W. B., Roberts, A., Perez, A., Cao, C., & Kupfer, S. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00425.x · Cited by 143 · see citing works
Self-citationSica, D. A., White, W. B., Weber, M. A., Bakris, G. L., Pérez, A., Cao, C., Handley, A., & Kupfer, S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00482.x · Cited by 117 · see citing works
Self-citationAngiotensin II Receptor Inhibition
Messerli, F. H. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440160069010 · Cited by 117 · see citing works
Persistence with Treatment in Newly Treated Middle-Aged Patients with Essential Hypertension
Perreault, S. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e548 · Cited by 91 · see citing works
Current Diagnosis and Treatment Cardiology
Goldstein, J. A. (2017) · Cited by 65 · see citing works
Baumgart, P., Walger, P., Jürgens, U., et al. (1990) · Journal of Molecular Medicine · doi:10.1007/bf01647580 · Cited by 48 · see citing works
Appel, G. B., & Appel, A. S. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.005 · Cited by 29 · see citing works
The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease.
Weber, M. A. (2002) · PubMed · Cited by 21 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
Self-citation
- Authors
- Bönner, G., Bakris, G. L., Sica, D., Weber, M. A., White, W. B., Perez, A., Cao, C., Handley, A., & Kupfer, S.
- Affiliations
- University of Chicago (US)
- Virginia Commonwealth University (US)
- SUNY Downstate Health Sciences University (US)
- University of Connecticut (US)
- Takeda (United States) (US)
- Corresponding author
- Bönner, G
- Venue
- Journal of Human Hypertension
- Published
- 2013-03-21
- Volume
- 27
- Issue
- 8
- Pages
- 479-486
- ISSN
- 0950-9240 (ISSN-L)
- 1476-5527
- PMC
- PMC3715765
- OpenAlex
- W2068936861
- Cited by
- 61
- References
- 33
- Citations by year
- 2026: 3 · 2024: 6 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 7 · 2019: 3 · 2018: 2 · 2017: 7 · 2016: 6 · 2015: 5 · 2014: 4 · 2013: 5
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Human Hypertension (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- azilsartan medoxomil, ramipril, hypertension, antihypertensive efficacy, angiotensin receptor blockers, ACE inhibitors, systolic blood pressure, drug tolerability, adverse events, dose titration
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Benzimidazoles, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Oxadiazoles, Ramipril, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
